Trastuzumab binds HER2 on tumor cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells) to induce antibody-dependent cellular cytotoxicity; it may also contribute via complement activation and HER2 signaling blockade leading to apoptosis.